Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies (Journal article)

Pavlidis, N. A./ Manoussakis, M. N./ Germanidis, G. S./ Moutsopoulos, H. M.


Full metadata record
DC FieldValueLanguage
dc.contributor.authorPavlidis, N. A.en
dc.contributor.authorManoussakis, M. N.en
dc.contributor.authorGermanidis, G. S.en
dc.contributor.authorMoutsopoulos, H. M.en
dc.date.accessioned2015-11-24T18:51:59Z-
dc.date.available2015-11-24T18:51:59Z-
dc.identifier.issn0098-1532-
dc.identifier.urihttp://olympias.lib.uoi.gr/jspui/handle/123456789/18338-
dc.rightsDefault Licence-
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell/*blood/pathologyen
dc.subjectLymphoma, Non-Hodgkin/*blood/pathologyen
dc.subjectMaleen
dc.subjectMultiple Myeloma/*blood/pathologyen
dc.subjectNeoplasm Recurrence, Local/blooden
dc.subjectNeoplasm Stagingen
dc.subjectReceptors, Interleukin-2/*biosynthesisen
dc.titleSerum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignanciesen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/1727208-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/mpo.2950200106/asset/2950200106_ftp.pdf?v=1&t=h0niqg4f&s=5fb864ef105fa4e072a4c4ccdb8d28fc5faba0a0-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1992-
heal.abstractThe levels of soluble interleukin-2 receptors (sIL-2R) were determined in the serum of 53 patients with B-cell lymphoproliferative malignancies, including 31 patients with non-Hodgkin lymphomas (NHL), 16 with chronic lymphocytic leukemia (CLL), and 6 with multiple myeloma. In addition, serum samples from 40 patients with various solid tumors as well as from 53 healthy individuals were used as controls. It was found that the mean serum levels of sIL-2R were significantly increased (P less than 0.001) in NHL (mean +/- standard error of the mean 2,327 +/- 320 units/ml) and CLL patients (2517 +/- 451 units/ml) as compared to normal controls (207 +/- 17 units/ml). No such difference was observed when the serum sIL-2R levels of patients with multiple myeloma or solid tumors were analyzed. Serum sIL-2R levels were closely related to the clinical stage, the presence of B-symptoms, and the disease activity of patients with NHL and CLL. In fact, response to chemotherapy was followed by marked decrease or normalization of sIL-2R levels, while in a number of patients sIL-2R values were even able to predict disease relapse. Finally, no association with histologic grade in NHL patients, could be demonstrated. We conclude that serum sIL-2R (1) are increased only in B-NHL and B-CLL but not in myeloma patients, (2) are related to the tumor burden, and (3) can serve as a valuable tumor marker for the monitoring of patients treatment.en
heal.journalNameMed Pediatr Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Pavlidis-1992-Serum-soluble interl.pdf466.27 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/18338
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.